Study of TGI-6 for advanced solid tumors
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called TGI-6 in people with advanced solid tumors, including colorectal cancer and other cancers that have a specific marker (B7-H6). The goal is to see if it is safe and effective for those who have run out of standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor cancer that has spread (advanced) or cannot be removed by surgery.
- You must have tried all standard therapies for your cancer, or you cannot tolerate them, or no standard therapy exists.
- For most cancers (except colorectal), a tumor sample must be tested to confirm a marker called B7-H6 is present.
- You cannot have untreated or active brain metastases.
- You cannot have an active autoimmune disease that requires ongoing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental injection called GKL-006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and helps shrink or control the cancer.
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
This Phase 1 trial tests GT101, an injection made from your own tumor-fighting immune cells, for advanced solid cancers that can’t be removed with surgery. It’s mainly aimed at checking safety and early signs of whether the treatment may work.
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.